2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Leslie M. Randall, MD, MAS, discusses the unmet needs in platinum-resistant ovarian cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Leslie M. Randall, MD, MAS, professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massey Cancer Center, VCU Health, discusses the unmet needs in platinum-resistant ovarian cancer.
Limited treatment options are available for patients with platinum-resistant ovarian cancer, representing a clear unmet need, explains Randall.
Although chemotherapy is the standard of care, the response rate is approximately 15% in this setting, says Randall.
As such, the FDA accelerated approval pathway, which offers a potential opportunity to fulfill these unmet needs, still stands in the United States, Randall concludes.